AI Insight
The CARDIO-TTRansform clinical trial testing eplontersen as a treatment for transthyretin-mediated amyloid cardiomyopathy failed to achieve its primary efficacy endpoint. The results were presented at the European Society of Cardiology Congress 2026, indicating that the investigational therapy did not demonstrate the intended therapeutic benefit in this patient population.
Why it matters
This negative trial result is significant for patients with transthyretin-mediated amyloid cardiomyopathy, a serious cardiac condition with limited treatment options. The failure to meet the primary endpoint means this particular therapeutic approach will likely not advance to regulatory approval, necessitating continued research into alternative treatments for this condition.
Understand the Science
The CARDIO-TTRansform trial investigating eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy did not meet its primary efficacy endpoint, according to results presented in a Hot Line session at ESC Congress 2026.
Source: Eplontersen trial fails to meet primary endpoint in transthyretin-mediated amyloid cardiomyopathy